



an Open Access Journal by MDPI

## A ‘One-Health Focus’ on Natural Aquatic Toxins

Guest Editors:

**Dr. Andrew Turner**

Centre for Environment, Fisheries  
and Aquaculture Science,  
Weymouth Laboratory,  
Lowestoft, UK

**Dr. Alison Robertson**

Marine Toxicology & Chemistry,  
Department of Marine Sciences,  
University of South Alabama,  
Mobile, AL 36688, USA

Deadline for manuscript  
submissions:

**closed (10 May 2020)**

### Message from the Guest Editors

Natural aquatic toxins are produced naturally by certain species of algae and bacteria in a wide range of aquatic environments and may subsequently accumulate in aquatic foodstuffs such as shellfish and fish, causing significant global risk to consumers. In addition, toxins are known to impact directly and indirectly upon both animal and ecosystem health. Different toxin groups exist, many of which are regulated to ensure consumer protection, although in recent years other groups have emerged, causing varying degrees of hazard and associated human health risks. Given the number and complexity of toxin congeners potentially associated with each toxin class, and notable differences in relative toxicity and modes of action, there is a continuing need to assess the developing threats from marine shellfish and fish toxins. With the increase in new toxin findings and exposure pathways over the last five years, this Special Issue of Marine Drugs is taking a “One-Health” focus on recent advances in marine and freshwater shellfish toxin research, which cause impacts on human, animal, and environmental health.



[mdpi.com/si/35562](https://mdpi.com/si/35562)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

## Contact Us

---

*Marine Drugs*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
[@Marine\\_Drugs](https://twitter.com/Marine_Drugs)